The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

Bluebird urged shareholders to back a take-private deal that could close imminently. Elsewhere, Unity Biotechnology began a strategic review and Mersana announced plans to cut more than half its ...